Bailard’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bailard’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-29,500	Closed	-$122K	–	745
2022 Q2	$122K	Buy	+29,500	New	+$161K	﹤0.01%	647

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's RYTM Position: Q3 2022 in Review

Bailard sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2022, closing a stake of 29,500 shares — an estimated $122K sold.

Bailard first reported a position in RYTM in Q2 2022 and held it in 1 quarter. The position peaked at $122K in Q2 2022. 101 funds tracked by Wall St. Rank hold RYTM as of Q3 2022.

Bailard reported no remaining Rhythm Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 29,500 Rhythm Pharmaceuticals shares in Q3 2022, an estimated $122K.
Bailard first reported a position in Rhythm Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Bailard's Rhythm Pharmaceuticals position peaked at $122K in Q2 2022.
101 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.